tiprankstipranks
Advertisement
Advertisement
Heron announces U.S. district court decision regarding Cinvanti patents
PremiumThe FlyHeron announces U.S. district court decision regarding Cinvanti patents
4d ago
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility
Premium
Company Announcements
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility
26d ago
Heron Therapeutics Signals Recovery Despite Soft Q1
Premium
Company Announcements
Heron Therapeutics Signals Recovery Despite Soft Q1
26d ago
Heron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward
PremiumRatingsHeron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward
2M ago
Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus
Premium
Company Announcements
Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus
2M ago
Heron Therapeutics Signals Profitable Growth After Strong Quarter
Premium
Company Announcements
Heron Therapeutics Signals Profitable Growth After Strong Quarter
3M ago
Heron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum
PremiumRatingsHeron Therapeutics: Undervalued Growth Story Driven by Zynrelef and Aponvie Momentum
5M ago
Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue
Premium
Company Announcements
Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue
5M ago
Heron Therapeutics: ZYNRELEF-Led Commercial Inflection and Undemanding Valuation Support Buy Rating and $6 Target
Premium
Ratings
Heron Therapeutics: ZYNRELEF-Led Commercial Inflection and Undemanding Valuation Support Buy Rating and $6 Target
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100